Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: health  healthcare  sentara  leigh  hospital  treatment  cdifficile  cure  infection  copper  oxide  multivu  7955751  health  healthcare  sentara  leigh  hospital  treatment  cdifficile  cure  infection  copper  oxide  multivu  7955751  euclid  cdi  hospital  clinic  diagnosis  europe  awareness  test  healthcare  multivu  71400524  gmf  une  vie  application  information  funeraire  deces  demarches  proches  famille  succession  cout  simulateur  multivu  63484  sanofi  pasteur  clostridium  difficile  infection  vaccine  bacteria  cdiffense  health  study  multivu  62652  diagnosis  management  cdi  health  europe  clostridium  difficile  infection  hospital  acquired  disease  multivu  60637  dificid  fda  approval  drug  cdad  clostridium  treatment  disease  optimer  pharmaceuticals  health  healthcare  multivu  50177  fidaxomicin  clostridium  difficile  infection  cdi  hospital  acquired  antibiotics  multivu  47526 
Search // difficile
Results 1-8 of 8 for ' difficile ' (0 seconds)
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare. The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016. To view the multimedia release go to: http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Categories // Miscellaneous 
Added: 1349 days ago by MultiVuVideos
Runtime: 3m35s | Views: 105 | Comments: 0
Not yet rated
 

 

 

A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare. The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016. To view the multimedia release go to: http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Categories // Miscellaneous 
Added: 1350 days ago by MultiVuVideos
Runtime: 5m33s | Views: 209 | Comments: 0
Not yet rated
 

 

 

The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
Categories // Science and Technology 
Added: 2247 days ago by MultiVuVideos
Runtime: 4m43s | Views: 317 | Comments: 1
Not yet rated
 

 

 

Tout le monde peut être confronté au décès d’un proche et ce moment difficile s’accompagne d’une multitude de démarches administratives auxquelles les familles sont peu préparées. Afin d’aider tous ceux qui doivent faire face à la disparition d’un proche ou qui souhaitent anticiper plus sereinement l’avenir en protégeant leur famille, la GMF a développé l’application « Une Vie », téléchargeable gratuitement sur l’App Store et Google Play Store. Pour accéder au Multimedia Nouvelles de presse, allez à http://www.multivu.com/mnr/63484-gmf-une-vie-vous-accompagne-dans-les-moments-difficiles
Added: 2433 days ago by MultiVuVideos
Runtime: 1m39s | Views: 853 | Comments: 1
Not yet rated
 

 

 

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide. To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Categories // Business  Science and Technology 
Added: 2527 days ago by MultiVuVideos
Runtime: 1m59s | Views: 1092 | Comments: 1
Not yet rated
 

 

 

Urgent action is needed to improve the diagnosis and management of CDI, which is the main cause of hospital-acquired (nosocomial) diarrhoea in industrialised countries.2 In a report launched today, during a meeting hosted by the European Healthcare and Hospital Federation (HOPE), experts from across Europe highlight the current deficiencies in the management of CDI and outline the steps that are needed to address them. To view Multimedia News Release, go to http://www.multivu.com/mnr/60637-astellas-report-diagnosis-management-CDI
Categories // News and Politics 
Added: 2636 days ago by MultiVuVideos
Runtime: 1m33s | Views: 493 | Comments: 0
Not yet rated
 

 

 

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Categories // News and Politics 
Added: 3328 days ago by MultiVuVideo
Runtime: 2m15s | Views: 6818 | Comments: 0
Not yet rated
 

 

 

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
Categories // News and Politics 
Added: 3436 days ago by MultiVuVideo
Runtime: 4m18s | Views: 5132 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2020 ClipMoon.com. All rights reserved.